Literature DB >> 27133344

Administration of low molecular weight and unfractionated heparin during percutaneous coronary intervention.

Sadegh Ali-Hassan-Sayegh1, Seyed Jalil Mirhosseini2, Azadeh Shahidzadeh2, Parisa Mahdavi2, Mahbube Tahernejad2, Fatemeh Haddad2, Mohammad Reza Lotfaliani2, Anton Sabashnikov3, Aron-Frederik Popov3.   

Abstract

This systematic review with meta-analysis sought to determine the efficacy and safety of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) on clinical outcomes following percutaneous coronary intervention. Medline, Embase, Elsevier, and web of knowledge as well as Google scholar literature were used for selecting appropriate studies with randomized controlled design. After screening 445 studies, a total of 23 trials (including a total of 43,912 patients) were identified that reported outcomes. Pooled analysis revealed that LMWH compared to UFH could significantly increase thrombolysis in myocardial infarction grade 3 flow (p<0.001), which was associated with similar target vessel revascularization (p=0.6), similar incidence of stroke (p=0.7), and significantly lower incidence of re-myocardial infarction (p<0.001), major bleeding (p=0.02) and mortality (p<0.001). Overall, LMWH was shown to be a useful type of heparin for patients with MI undergoing PCI, due to its higher efficacy and lower rate of complication compared to UFH. It is also associated with increased myocardial perfusion, decreased major hemorrhage, and mortality.
Copyright © 2016 Cardiological Society of India. All rights reserved.

Entities:  

Keywords:  Low molecular weight heparin; Myocardial infarction; Outcome; Percutaneous coronary intervention; Unfractionated heparin

Mesh:

Substances:

Year:  2016        PMID: 27133344      PMCID: PMC4867946          DOI: 10.1016/j.ihj.2016.01.014

Source DB:  PubMed          Journal:  Indian Heart J        ISSN: 0019-4832


  44 in total

1.  2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons.

Authors:  R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar
Journal:  J Am Coll Cardiol       Date:  2011-05-10       Impact factor: 24.094

Review 2.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.

Authors:  J Hirsh; T E Warkentin; S G Shaughnessy; S S Anand; J L Halperin; R Raschke; C Granger; E M Ohman; J E Dalen
Journal:  Chest       Date:  2001-01       Impact factor: 9.410

3.  Quality of care among elderly patients hospitalized with unstable angina.

Authors:  C N Shahi; S S Rathore; Y Wang; R Thakur; W C Wu; J M Lewis; M K Petrillo; M J Radford; H M Krumholz
Journal:  Am Heart J       Date:  2001-08       Impact factor: 4.749

4.  Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.

Authors:  David Brieger; Jean-Philippe Collet; Johanne Silvain; Antoine Landivier; Olivier Barthélémy; Farzin Beygui; Anne Bellemain-Appaix; Anne Mercadier; Remi Choussat; Nicolas Vignolles; Dominique Costagliola; Gilles Montalescot
Journal:  Catheter Cardiovasc Interv       Date:  2011-02-01       Impact factor: 2.692

Review 5.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Authors:  S Yusuf; S Reddy; S Ounpuu; S Anand
Journal:  Circulation       Date:  2001-11-27       Impact factor: 29.690

6.  Intravenous enoxaparin versus unfractionated heparin in unselected patients undergoing percutaneous coronary interventions: the Zurich enoxaparin versus unfractionated heparin in PCI study (ZEUS).

Authors:  Osmund Bertel; David Ramsay; Tobias Wettstein; David J Kurz; Irene Stettler; Edwin Straumann; Juergen Frielingsdorf; Dominik Maurer; Barbara Naegeli
Journal:  EuroIntervention       Date:  2010-08       Impact factor: 6.534

7.  [Use of a combination of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomized pilot study].

Authors:  Guillermo Galeote; Monser Hussein; Nicolás Sobrino; Luis Calvo; Angel Sánchez-Recalde; José A Sobrino
Journal:  Rev Esp Cardiol       Date:  2002-12       Impact factor: 4.753

8.  ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.

Authors:  Stefanie Schulz; Julinda Mehilli; Franz-Josef Neumann; Tibor Schuster; Steffen Massberg; Christian Valina; Melchior Seyfarth; Jürgen Pache; Karl-Ludwig Laugwitz; Hans-Joachim Büttner; Gjin Ndrepepa; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983

9.  Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.

Authors:  Philippe Gabriel Steg; Sanjit S Jolly; Shamir R Mehta; Rizwan Afzal; Denis Xavier; Hans-Jurgen Rupprecht; Jose L López-Sendón; Andrzej Budaj; Rafael Diaz; Alvaro Avezum; Petr Widimsky; Sunil V Rao; Susan Chrolavicius; Brandi Meeks; Campbell Joyner; Janice Pogue; Salim Yusuf
Journal:  JAMA       Date:  2010-08-31       Impact factor: 56.272

10.  Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris.

Authors:  M M Rabah; J Premmereur; M Graham; J Fareed; D A Hoppensteadt; L L Grines; C L Grines
Journal:  Am J Cardiol       Date:  1999-12-15       Impact factor: 2.778

View more
  1 in total

1.  Low-Molecular-Weight Heparin-Functionalized Chitosan-Chondroitin Sulfate Hydrogels for Controlled Release of TGF-β3 and in vitro Neocartilage Formation.

Authors:  You-Rong Chen; Zhu-Xing Zhou; Ji-Ying Zhang; Fu-Zhen Yuan; Bing-Bing Xu; Jian Guan; Chao Han; Dong Jiang; Yan-Yu Yang; Jia-Kuo Yu
Journal:  Front Chem       Date:  2019-11-01       Impact factor: 5.221

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.